Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. (2nd January 2016)

• Record Type: Journal Article
• Authors: Diri, Halit; Karaburgu, Sulbiye; Acmaz, Banu; Unluhizarci, Kursad; Tanriverdi, Fatih; Karaca, Zuleyha; Kelestimur, Fahrettin
• Is Part Of: Gynecological endocrinology. Volume 32:Number 1(2016:Jan.)
• Page Start: 42
• Page End: 45
• Publication Date: 2016-01-02
• Subjects: Metformin -- PCOS -- spironolactone -- treatment; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.3109/09513590.2015.1080679
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS). Thirty-seven patients with PCOS were randomly assigned to receive spironolactone 100 mg/d (spironolactone group, 18 patients) or spironolactone 100 mg/d plus metformin 2000 mg/d (combination group, 19 patients) for 12 months. BMI, modified Ferriman–Gallway score (FGS), serum levels of regarding hormones, and homeostasis model assessment of insulin resistance (HOMA-IR) index were assessed before and after the treatments. Six patients in the spironolactone group and four patients in the combination group reported inter-menstrual vaginal bleeding during treatments. In hirsutism scores, the spironolactone therapy resulted in 25.2% reduction, while combination therapy resulted in 28.3% reduction ( p > 0.05, between groups). When the groups were compared in terms of percent changes in BMI, FGS, HOMA-IR, and hormone values other than free testosterone, no significant difference was noted. In the present study, FGSs were significantly decreased in both groups; however, combination therapy was not more effective than spironolactone alone in terms of BMI, FGS, hormone levels, or insulin resistance.